NASDAQ:IMCR Immunocore (IMCR) Stock Price, News & Analysis $30.10 -0.37 (-1.21%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immunocore Stock (NASDAQ:IMCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immunocore alerts:Sign Up Key Stats Today's Range$30.01▼$30.7650-Day Range$24.53▼$30.8152-Week Range$23.15▼$62.74Volume127,223 shsAverage Volume433,976 shsMarket Capitalization$1.51 billionP/E RatioN/ADividend YieldN/APrice Target$59.44Consensus RatingHold Company OverviewImmunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Read More… Immunocore Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreIMCR MarketRank™: Immunocore scored higher than 61% of companies evaluated by MarketBeat, and ranked 809th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingImmunocore has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 6 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageImmunocore has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunocore's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immunocore are expected to decrease in the coming year, from ($0.94) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunocore is -31.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunocore is -31.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunocore has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunocore's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.77% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 25.1, which indicates bearish sentiment.Change versus previous monthShort interest in Immunocore has recently decreased by 4.95%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunocore does not currently pay a dividend.Dividend GrowthImmunocore does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.77% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 25.1, which indicates bearish sentiment.Change versus previous monthShort interest in Immunocore has recently decreased by 4.95%, indicating that investor sentiment is improving. News and Social Media3.0 / 5News Sentiment1.31 News SentimentImmunocore has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Immunocore this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for IMCR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Immunocore insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,994,085.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.40% of the stock of Immunocore is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunocore's insider trading history. Receive IMCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. Email Address IMCR Stock News HeadlinesImmunocore Holdings: A Name On My Watch ListApril 27 at 9:22 AM | seekingalpha.comJ.P. Morgan Remains a Buy on Immunocore Holdings (IMCR)April 15, 2025 | markets.businessinsider.comNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. April 30, 2025 | Paradigm Press (Ad)Immunocore Holdings (IMCR) Gets a Buy from NeedhamApril 10, 2025 | markets.businessinsider.comImmunocore price target lowered to $33 from $38 at MizuhoApril 8, 2025 | markets.businessinsider.comImmunocore to present at upcoming investor conferencesApril 2, 2025 | globenewswire.comInsiders Make Huge Purchases of These 4 Biotech StocksMarch 26, 2025 | 247wallst.comImmunocore Holdings plc (IMCR): Among Stocks Receiving the Most Insider Love in MarchMarch 25, 2025 | msn.comSee More Headlines IMCR Stock Analysis - Frequently Asked Questions How have IMCR shares performed this year? Immunocore's stock was trading at $29.50 on January 1st, 2025. Since then, IMCR shares have increased by 2.8% and is now trading at $30.33. View the best growth stocks for 2025 here. How were Immunocore's earnings last quarter? Immunocore Holdings plc (NASDAQ:IMCR) announced its quarterly earnings data on Wednesday, November, 6th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.50. The business's revenue for the quarter was up 23.7% on a year-over-year basis. When did Immunocore IPO? Immunocore (IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO. Who are Immunocore's major shareholders? Immunocore's top institutional shareholders include Principal Financial Group Inc. (0.96%), Envestnet Asset Management Inc. (0.13%), Hennion & Walsh Asset Management Inc. (0.13%) and GAMMA Investing LLC (0.04%). Insiders that own company stock include Bros Advisors Lp Baker and Leger Tina Amber St. View institutional ownership trends. How do I buy shares of Immunocore? Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunocore own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunocore investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings11/06/2024Today4/30/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMCR CIK1671927 Webwww.immunocore.com Phone44-12-3543-8600FaxN/AEmployees320Year FoundedN/APrice Target and Rating Average Stock Price Target$59.44 High Stock Price Target$100.00 Low Stock Price Target$24.00 Potential Upside/Downside+95.8%Consensus RatingHold Rating Score (0-4)2.45 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,290,000.00 Net Margins-15.87% Pretax Margin-18.14% Return on Equity-12.84% Return on Assets-5.09% Debt Debt-to-Equity Ratio1.03 Current Ratio3.78 Quick Ratio3.76 Sales & Book Value Annual Sales$310.20 million Price / Sales4.90 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book4.09Miscellaneous Outstanding Shares50,068,000Free Float45,480,000Market Cap$1.52 billion OptionableOptionable Beta0.75 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:IMCR) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.